{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:15:26Z","timestamp":1791296126804,"version":"4.1.0"},"reference-count":170,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T00:00:00Z","timestamp":1081814400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Numerous recent investigations have pointed to a key role of the proinflammatory, pleiotropic cytokine tumor necrosis factor\u2010\u03b1 (TNF\u2010\u03b1) in host defense and inflammatory processes. TNF overexpression has been found in lesional skin and in the circulation of psoriatic patients, and it was suggested that TNF\u2010\u03b1 is crucial in this and other immune diseases. Several approaches to inhibit TNF\u2010\u03b1 activity have been developed. These include three different neutralizing antibodies to TNF\u2010\u03b1 as well as three different soluble TNF\u2010\u03b1 receptors with characteristic properties designed to bind the 17\u2010KDa soluble trimeric TNF\u2010\u03b1 and the 26\u2010KDa membrane\u2010bound form of TNF\u2010\u03b1. Clinical trials have demonstrated significant antipsoriatic effects, and it is likely that blocking TNF\u2010\u03b1 will become an important therapeutic option. The data available from these trials contribute to further understanding of the disease by demonstrating the major role of TNF\u2010\u03b1. An in\u2010depth understanding of the regulation of TNF gene expression, protein production, receptor expression, and signaling pathways may lead to further, potentially important novel therapeutic strategies and antipsoriatic active small molecules, suitable for oral application in the future. Here we review the current knowledge of TNF biology, the approaches to inhibit TNF activity, and their clinical and immunological effects in psoriasis. In addition, the host\u2010defense effects and chronic TNF\u2010blocking activity are discussed.<\/jats:p>","DOI":"10.1111\/j.0906-6705.2004.00205.x","type":"journal-article","created":{"date-parts":[[2004,4,13]],"date-time":"2004-04-13T15:51:34Z","timestamp":1081871494000},"page":"193-222","source":"Crossref","is-referenced-by-count":164,"title":["Biology of tumor necrosis factor\u2010\u03b1\u2013 implications for psoriasis"],"prefix":"10.1111","volume":"13","author":[{"given":"Arndt J. G.","family":"Schottelius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyle L.","family":"Moldawer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A.","family":"Dinarello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khusru","family":"Asadullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Sterry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Carl K.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,4,13]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.5.681"},{"key":"e_1_2_11_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI5857"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.2.187"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4906(01)02119-6"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1992.tb08394.x"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.11.3949"},{"key":"e_1_2_11_8_2","first-page":"39","article-title":"Human tumour necrosis factor: structure and receptor interactions","volume":"131","author":"Aggarwal B B","year":"1987","journal-title":"Ciba Found Symp"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.18.6060"},{"key":"e_1_2_11_10_2","volume-title":"The Molecules and Their Emerging Role in Medicine","author":"Beutler B","year":"1992"},{"key":"e_1_2_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(88)90486-2"},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/385733a0"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5392.1281"},{"key":"e_1_2_11_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199606273342607"},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-1119(93)90280-G"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.171.2.465"},{"key":"e_1_2_11_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/19.15.4154"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80038-2"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.45.31868"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(97)80082-9"},{"issue":"6","key":"e_1_2_11_21_2","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.4049\/jimmunol.159.6.2867","article-title":"DBA\/1 mice expressing the human TNF\u2010alpha transgene develop a severe, erosive arthritis","volume":"159","author":"Butler D M","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_11_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830271018"},{"key":"e_1_2_11_23_2","first-page":"S120","article-title":"Clinical and histopathologic characterization of arthritis in male and female tumor necrosis factor\u2010alpha knockout (TNF\u2010alpha\u2013\/\u2013) and membrane\u2010bound TNF\u2010alpha transgenic (TNF\u2010alphaTgA86) mice injected with mycoplasma pulmonies or mycoplasma arthritidis","volume":"42","author":"Chlipala C K","year":"1999","journal-title":"Arthritis Rheum"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.2901181.x"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.1997.3181214.x"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-2478(94)00195-W"},{"key":"e_1_2_11_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.16.7375"},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.20.9784"},{"key":"e_1_2_11_29_2","first-page":"510","article-title":"Evolution of collagen arthritis in mice is arrested by treatment with anti\u2010tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor","volume":"77","author":"Piguet P F","year":"1992","journal-title":"Immunology"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830250647"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2391::AID-ANR3>3.0.CO;2-F"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.2008.i40"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.23704"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1998.0372"},{"issue":"9","key":"e_1_2_11_35_2","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.4049\/jimmunol.163.9.5049","article-title":"IL\u20101alphabeta blockade prevents cartilage and bone destruction in murine type II collagen\u2010induced arthritis, whereas TNF\u2010alpha blockade only ameliorates joint inflammation","volume":"163","author":"Joosten L A","year":"1999","journal-title":"J Immunol"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390513"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12724"},{"key":"e_1_2_11_38_2","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood.V79.3.693.693","article-title":"Effects of leukocytes after injection of tumor necrosis factor into healthy humans","volume":"79","author":"Van Der Poll T","year":"1992","journal-title":"Blood"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/164.3.599"},{"key":"e_1_2_11_40_2","first-page":"E457","article-title":"Tumor necrosis factor mimics the metabolic response to acute infection in health humans","volume":"261","author":"Van Der Poll T","year":"1991","journal-title":"Am J Physiol"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.3.729"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/80.13.1039"},{"issue":"5","key":"e_1_2_11_43_2","first-page":"539","article-title":"A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy","volume":"8","author":"Zamkoff K W","year":"1989","journal-title":"J Biol Response Mod"},{"key":"e_1_2_11_44_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI694"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-199605000-00007"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.2008.i73"},{"key":"e_1_2_11_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/1043-4666(94)90048-5"},{"key":"e_1_2_11_48_2","doi-asserted-by":"crossref","first-page":"11966","DOI":"10.1016\/S0021-9258(18)80161-2","article-title":"Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor","volume":"264","author":"Seckinger P","year":"1989","journal-title":"J Biol Chem"},{"key":"e_1_2_11_49_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.167.4.1511"},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.13.5188"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1086\/317605"},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.2.570"},{"issue":"25","key":"e_1_2_11_53_2","doi-asserted-by":"crossref","first-page":"18542","DOI":"10.1016\/S0021-9258(17)46661-0","article-title":"Ligand passing: the 75\u2010kd tumor necrosis factor (TNF) receptor recrutits TNF for signaling by the 55 Kd TNF receptor","volume":"268","author":"Tartaglia L A","year":"1993","journal-title":"J Biol Chem"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.153.5.1963"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.3136"},{"key":"e_1_2_11_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/385540a0"},{"key":"e_1_2_11_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81318-5"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5288.784"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80152-1"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.2.943"},{"key":"e_1_2_11_61_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.2000.278.5.R1202"},{"key":"e_1_2_11_62_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.1.165"},{"key":"e_1_2_11_63_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.179.4.1185"},{"key":"e_1_2_11_64_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.2.607"},{"key":"e_1_2_11_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90134-C"},{"key":"e_1_2_11_66_2","doi-asserted-by":"publisher","DOI":"10.1038\/364798a0"},{"key":"e_1_2_11_67_2","doi-asserted-by":"publisher","DOI":"10.1038\/372560a0"},{"key":"e_1_2_11_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90192-2"},{"key":"e_1_2_11_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830271119"},{"key":"e_1_2_11_70_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.188.7.1343"},{"key":"e_1_2_11_71_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI118739"},{"key":"e_1_2_11_72_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri802"},{"key":"e_1_2_11_73_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.9.768"},{"key":"e_1_2_11_74_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.397"},{"key":"e_1_2_11_75_2","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.4049\/jimmunol.144.9.3347","article-title":"Quantitative analysis of cytokine gene expression in rheumatoid arthritis","volume":"144","author":"Firestein G S","year":"1990","journal-title":"J Immunol"},{"key":"e_1_2_11_76_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780340908"},{"issue":"10","key":"e_1_2_11_77_2","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.4049\/jimmunol.146.10.3365","article-title":"Cytokines in chronic inflammatory arthritis. VI. Analysis of the synovial cells involved in granulocyte\u2010macrophage colony\u2010stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL\u20101 and tumor necrosis factor\u2010alpha","volume":"146","author":"Alvaro\u2010Gracia J M","year":"1991","journal-title":"J Immunol"},{"key":"e_1_2_11_78_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114908"},{"key":"e_1_2_11_79_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI114908"},{"key":"e_1_2_11_80_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-3083.1999.00458.x"},{"key":"e_1_2_11_81_2","first-page":"145","article-title":"The tumor necrosis factor family of receptors\/ligands in the serum of patients with rheumatoid arthritis","volume":"9","author":"Robak T","year":"1998","journal-title":"Eur Cytokine Netw"},{"issue":"3","key":"e_1_2_11_82_2","first-page":"406","article-title":"Soluble receptors for tumor necrosis factor and interleukin\u20102 in serum and synovial fluid of patients with rheumatoid arthritis, reactive arthritis and osteoarthritis","volume":"22","author":"Steiner G","year":"1995","journal-title":"J Rheumatol"},{"key":"e_1_2_11_83_2","doi-asserted-by":"publisher","DOI":"10.1038\/322547a0"},{"key":"e_1_2_11_84_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1993.tb03457.x"},{"key":"e_1_2_11_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830220835"},{"key":"e_1_2_11_86_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb02687.x"},{"key":"e_1_2_11_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1994.tb06244.x"},{"key":"e_1_2_11_88_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02505228"},{"issue":"1","key":"e_1_2_11_89_2","first-page":"129","article-title":"Cellular localization of interleukin\u20108 and its inducer, tumor necrosis factor\u2010alpha in psoriasis","volume":"138","author":"Nickoloff B J","year":"1991","journal-title":"Am J Pathol"},{"key":"e_1_2_11_90_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12371679"},{"key":"e_1_2_11_91_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1999.02926.x"},{"issue":"8","key":"e_1_2_11_92_2","first-page":"1544","article-title":"Patterns of cytokine production in psoriatic synovium","volume":"25","author":"Ritchlin C","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_11_93_2","first-page":"518","article-title":"Highly increased levels of tumor necrosis factor\u2010alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid","volume":"24","author":"Partsch G","year":"1997","journal-title":"J Rheumatol"},{"key":"e_1_2_11_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90326-L"},{"issue":"3","key":"e_1_2_11_95_2","first-page":"601","article-title":"Phase I\/II trial of recombinant methionyl human tumor necrosis factor binding protein PEGylated dimer in patients with active refractory rheumatoid arthritis","volume":"27","author":"Moreland L W","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_11_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707173370301"},{"key":"e_1_2_11_97_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400302"},{"key":"e_1_2_11_98_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1610-0387.2003.02044.x"},{"key":"e_1_2_11_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05246-0"},{"key":"e_1_2_11_100_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1997.tb00567.x"},{"key":"e_1_2_11_101_2","doi-asserted-by":"publisher","DOI":"10.1006\/abio.1999.4275"},{"key":"e_1_2_11_102_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.59.suppl_1.i44"},{"key":"e_1_2_11_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0198-8859(99)00068-3"},{"key":"e_1_2_11_104_2","first-page":"S243","article-title":"Neutralization of TNF by Lenercept. (TNFr55\u2010IgG1, Ro 45\u20132081) in patients with rheumatoid arthritis treated for 3 months; results of an US phase II trial","volume":"39","author":"Furst D","year":"1996","journal-title":"Arthritis Rheum"},{"key":"e_1_2_11_105_2","first-page":"S242","article-title":"(TNFR55\u2010IgG1, Ro 45\u20132081) in patients with rheumatoid arthritis treated for 3 months: results of a European phase II trial","volume":"39","author":"Sander O","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"9","key":"e_1_2_11_106_2","first-page":"S224","article-title":"Long term observation of 80 patients treated with TNF alpha receptor\u2010fusion protein (TNFR55\u2010 IgG1, Ro 45\u20132081)","volume":"40","author":"Sander O","year":"2000","journal-title":"Arthritis Rheum"},{"key":"e_1_2_11_107_2","first-page":"S58","article-title":"An assessment of the effect of anti\u2010drug antibody formation of the pharmacokinetics and pharmacodynamics of sTNFr55\u2010IgG (Ro 45\u20102081\u2010Lenercept [LEN]) (S.C.) in patients with rheumatoid arthritis","volume":"41","author":"Kneer J","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"1","key":"e_1_2_11_108_2","doi-asserted-by":"crossref","first-page":"414","DOI":"10.4049\/jimmunol.158.1.414","article-title":"Involvement of 26\u2010kDa cell associated TNFa in experimental hepatitis and exacerbation of liver injury with a matrix metalloproteinase inhibitor","volume":"158","author":"Solorzano C C","year":"1997","journal-title":"J Immunol"},{"key":"e_1_2_11_109_2","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.1998.84.4.1119"},{"key":"e_1_2_11_110_2","unstructured":"Serono.Positive results of onercept in psoriasis and psoriatic arthritis in phase II trials. 9th International Psoriasis Symposium in New York June 2003."},{"key":"e_1_2_11_111_2","unstructured":"Serono.Serono announces positive results of onercept in psoriasis and psoriatic arthritis in phase II trials. 6\u201022\u20102003. (http:\/\/www.serono.com)"},{"key":"e_1_2_11_112_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.105948"},{"key":"e_1_2_11_113_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00753.x"},{"key":"e_1_2_11_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04954-0"},{"key":"e_1_2_11_115_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.10"},{"key":"e_1_2_11_116_2","unstructured":"GottliebA B LiS EvansR MenterA.Infliximab in the treatment of psoriasis: results from the first 10 weeks of the phase II trial. 61th Annu Meet Am Acad Dermatol (March 21\u201326 2003 San Francisco)."},{"key":"e_1_2_11_117_2","unstructured":"BuchholzC.Promising new results reported for Remicade (infliximab) in the treatment of psoriasis. 3\u20101\u20102003. (http:\/\/www.centorcor.com)."},{"key":"e_1_2_11_118_2","unstructured":"GulliverWP Brown\u2010MaherT TabriziM.Low dose infliximab improves psoriasis. 61th Annu Meet Am Acad Dermatol (March 21\u201326 2003 San Francisco)."},{"key":"e_1_2_11_119_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2002.01543.x"},{"key":"e_1_2_11_120_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.5.644"},{"key":"e_1_2_11_121_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-002-0246-3"},{"key":"e_1_2_11_122_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10671"},{"key":"e_1_2_11_123_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04089.x"},{"key":"e_1_2_11_124_2","unstructured":"AntoniC SmolenJ.The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). 61th Annu Meet J Am Acad Dermatol (March 21\u201326 2003 San Francisco)."},{"key":"e_1_2_11_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02530-7"},{"key":"e_1_2_11_126_2","first-page":"S116","article-title":"Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept","volume":"20","author":"Mease P.","year":"2002","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_11_127_2","unstructured":"MeaseP J.Etanercept in psoriatic arthritis. 59th Annu Meet Am Acad Dermatol. Washington DC 2001."},{"issue":"7","key":"e_1_2_11_128_2","first-page":"4","article-title":"Etanercept inhibits radiographic progression in patients with psoriatic arthritis","volume":"120","author":"Gottlieb A B","year":"2003","journal-title":"J Investig Dermatol"},{"key":"e_1_2_11_129_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"issue":"7","key":"e_1_2_11_130_2","first-page":"4","article-title":"Efficacy and safety of Enbrel in patients with psoriasis: results of a phase 3 study","volume":"120","author":"Leonardi C","year":"2003","journal-title":"J Investig Dermatol"},{"key":"e_1_2_11_131_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030409"},{"issue":"7","key":"e_1_2_11_132_2","first-page":"4","article-title":"Prolonged response durability following etanercept monotherapy","volume":"120","author":"Gottlieb A B","year":"2003","journal-title":"J Invest Dermatol"},{"key":"e_1_2_11_133_2","doi-asserted-by":"publisher","DOI":"10.1159\/000063919"},{"key":"e_1_2_11_134_2","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12874977"},{"issue":"3","key":"e_1_2_11_135_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1006\/cyto.1995.0029","article-title":"Chimeric anti\u2010TNF\u2010alpha monoclonal antibody cA2 binds recombinant transmembrane TNF\u2010alpha and activates immune effector functions","volume":"7","author":"Scallon B J","year":"1995","journal-title":"Cytokine"},{"key":"e_1_2_11_136_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.28702"},{"key":"e_1_2_11_137_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.2001.0919"},{"key":"e_1_2_11_138_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.156.4.1646"},{"key":"e_1_2_11_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0898-6568(02)00080-3"},{"key":"e_1_2_11_140_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02871-3"},{"key":"e_1_2_11_141_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.14.1.649"},{"key":"e_1_2_11_142_2","unstructured":"Immunex Inc. Enbrel prescribing information. 11\u20101\u20101998."},{"key":"e_1_2_11_143_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2003.05294.x"},{"key":"e_1_2_11_144_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.137.12.1571"},{"key":"e_1_2_11_145_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2003.05663.x"},{"key":"e_1_2_11_146_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703094"},{"key":"e_1_2_11_147_2","unstructured":"HumeniukJ M GliptisE.Infliximab in the treatment of panniculitis. World Congress Of Dermatology Paris July 1\u20135 2002."},{"key":"e_1_2_11_148_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2001.119100"},{"key":"e_1_2_11_149_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200111223452118"},{"key":"e_1_2_11_150_2","doi-asserted-by":"publisher","DOI":"10.1038\/351355b0"},{"key":"e_1_2_11_151_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.103.8.1044"},{"key":"e_1_2_11_152_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10758"},{"key":"e_1_2_11_153_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10583"},{"key":"e_1_2_11_154_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.11151"},{"key":"e_1_2_11_155_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_11_156_2","first-page":"S166","article-title":"Tuberculosis and etanercept treatment","volume":"46","author":"Manadan A M","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"e_1_2_11_157_2","first-page":"86","article-title":"Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice","volume":"46","author":"Georgopoulos S","year":"1996","journal-title":"J Inflamm"},{"key":"e_1_2_11_158_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.301.2.418"},{"key":"e_1_2_11_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(03)00382-2"},{"key":"e_1_2_11_160_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2001.29035"},{"key":"e_1_2_11_161_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10847"},{"key":"e_1_2_11_162_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.6.561"},{"key":"e_1_2_11_163_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng0902-97"},{"issue":"4","key":"e_1_2_11_164_2","first-page":"263","article-title":"Impaired cutaneous cell\u2010mediated immunity in newly diagnosed rheumatoid arthritis","volume":"42","author":"Coaccioli S","year":"2000","journal-title":"Panminerva Med"},{"key":"e_1_2_11_165_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10679"},{"key":"e_1_2_11_166_2","first-page":"97","volume-title":"Xenobiotic Induced Inflammation: Roles of Cytokines and Growth Factors","year":"1994"},{"key":"e_1_2_11_167_2","unstructured":"Decision Resources I.TNF\u2010alpha inhibitors (Immune Inflammatory Disorders Study # 34). Waltham MA Decision Resources Inc. Immune and Inflammatory Disorders.2001."},{"key":"e_1_2_11_168_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1184"},{"key":"e_1_2_11_169_2","unstructured":"WankeL A BurgeD J.Etanercept improves health\u2010related quality of life in patients with psoriatic arthritis. 60th Annu Meet Am Acad Dermatol (February 22\u201327 New Orleans)2002."},{"key":"e_1_2_11_170_2","unstructured":"LebwohlM GottliebA B MeaseP J BurgeD J.Etanercept improves psoriasis activity in patients with psoriatic arthritis: results of a phase 3 multicenter clinical trial. 60th Annu Meet Am Acad Dermatol (February 22\u201327 New Orleans)2003."},{"key":"e_1_2_11_171_2","first-page":"234","article-title":"Efficacy of Enbrel in patients with psoriasis","volume":"119","author":"Gottlieb A B","year":"2002","journal-title":"J Invest Dermatol"}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.0906-6705.2004.00205.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.0906-6705.2004.00205.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T20:27:03Z","timestamp":1696969623000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.0906-6705.2004.00205.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":170,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1111\/j.0906-6705.2004.00205.x"],"URL":"https:\/\/doi.org\/10.1111\/j.0906-6705.2004.00205.x","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}